Overview

Add-on Dextromethorphan in Bipolar Disorders

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Dextromethorphan has been reported affording neuroprotection on dopaminergic neurons and having protective effect against inflammation-related neuron damage. These anti-inflammatory and neuroprotective effects of dextromethorphan would suggest potential clinical benefits of dextromethorphan add-on therapy to valproate for bipolar disorder patients. This hypothesis was based on the findings that the mood stabilizers have been reported to be neuroprotective through the release of neurotrophic factors such as GDNF from astroglia. Thus, the combination treatment of mood stabilizers and dextromethorphan might improve the therapeutic efficacy for bipolar disorder patients.
Phase:
Phase 3
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborators:
National Health Research Institutes, Taiwan
TTY Biopharm
Treatments:
Dextromethorphan
Valproic Acid